Veralto Corporation · VLTO · FY2026 Q1 · Calendar Q2 2026

Veralto Raises EPS Guidance on 7% Sales Growth, Announces $1B in Acquisitions

Veralto delivered a strong start to fiscal 2026, beating both EPS and revenue estimates and raising full-year EPS guidance. The quarter was marked by approximately 7% sales growth and 13% adjusted EPS growth, supported by secular demand for water quality solutions and steady packaging demand. Two strategic acquisitions totaling roughly $1 billion — In-Situ in Water Quality and GlobalVision in PQI — broaden the company's capabilities, while a new cost-optimization program targets margin expansion beginning in 2027. Management's confident tone and raised guidance contrast with acknowledged headwinds from tariffs, China municipal softness, and raw-material inflation. The stock's 4.5% post-earnings pop reversed into a 6.7% drift lower over subsequent sessions, suggesting investors may be weighing near-term integration risk and the deferred timeline for cost savings against the positive…

Reported After market closeNYSEIndustrials $24.27B market cap
100quality score

Company context

Snapshot as of publication

Veralto Corporation is a global provider specializing in critical solutions across water quality management, brand protection, and packaging aesthetics. Its operations are structured into two primary divisions: Water Quality (WQ) and Product Quality & Innovation (PQI). The WQ segment delivers advanced instrumentation and treatment technologies designed for the precise measurement, analysis, and purification of water. These solutions cater to a broad spectrum of applications, from residential and commercial settings to municipal systems, industrial processes, research facilities, and natural environments. Esteemed brands like Hach, Trojan Technologies, and ChemTreat fall under this segment, which also supplies essential chemical reagents, support services, and digital tools for comprehensive water management. The PQI segment focuses on enhancing product integrity and brand appeal.…

Earnings scorecard

Reported versus consensus
Reported EPS $1.07 Consensus $1
EPS surprise +7.0% Reported versus consensus
Reported revenue $1.42B Consensus $1.40B
Revenue surprise +1.6% Reported versus consensus

Earnings History

Estimate Beat Miss Match
VLTO EPS earnings history estimate and actual scatter chart 9 reported fiscal quarters and 4 future estimate-only quarters. Q4 '23 estimate $0.81 Q4 '23 actual $0.87, beat Q1 '24 estimate $0.76 Q1 '24 actual $0.84, beat Q2 '24 estimate $0.80 Q2 '24 actual $0.85, beat Q3 '24 estimate $0.85 Q3 '24 actual $0.89, beat Q2 '25 estimate $0.88 Q2 '25 actual $0.93, beat Q3 '25 estimate $0.95 Q3 '25 actual $0.99, beat Q4 '25 estimate $0.98 Q4 '25 actual $1.04, beat Q1 '26 estimate $1.00 Q1 '26 actual $1.07, beat Q2 '26 estimate $1.01 Q2 '26 actual $1.11, beat Q3 '26 estimate $1.07 Q4 '26 estimate $1.11 Q1 '27 estimate $1.15 Q2 '27 estimate $1.12
Show less

Analyst Consensus ?

ConsensusHold12 ratings
Bullish541.7%
Neutral758.3%
Bearish00.0%

Analyst 52W Price Targets

$94.71Current
$102Low
$108.86Average
$119High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Jul 31, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
Stifel Buy BuyMaintainJul 20, 2026
UBS Neutral NeutralMaintainMay 1, 2026
RBC Capital Sector Perform Sector PerformMaintainApr 30, 2026
Citigroup Neutral NeutralMaintainApr 30, 2026
Barclays Overweight OverweightMaintainApr 30, 2026
Jefferies Hold BuyDowngradeDec 10, 2025
BMO Capital Outperform OutperformMaintainNov 25, 2025
Baird Neutral NeutralMaintainJul 30, 2025
Show 4 more rating actions

Named analyst price targets

Upside is calculated against the persisted current price $94.71. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
Stifel NicolausAnalyst unavailable$111$93.81 +17.2%Jul 20, 2026
Wolfe ResearchAnalyst unavailable$109$92.12 +15.1%Jul 9, 2026
Robert W. BairdMichael Halloran$103$89.47 +8.8%Apr 30, 2026
BarclaysAnalyst unavailable$113$89.47 +19.3%Apr 30, 2026
Stifel NicolausNathan Jones$110$90.85 +16.1%Apr 14, 2026
BMO CapitalAnalyst unavailable$108$92.81 +14.0%Feb 11, 2026
UBSJoshua Spector$102$91.7 +7.7%Feb 6, 2026
Stifel NicolausNathan Jones$118$90.35 +24.6%Feb 5, 2026
RBC CapitalDeane Dray$102$89 +7.7%Feb 5, 2026
Robert W. BairdMichael Halloran$108$91.41 +14.0%Feb 5, 2026
See 18 more

Track every rating change on VLTO the moment it posts. Free to start.

Start free

Market reaction

event-close to next-session close
Stock move +4.5% Event window
SPY move -0.0% Same window
Abnormal move +4.5% Stock minus SPY
Volume 1.8× Versus trailing sessions
Subsequent drift -6.7% Up to 20 sessions
VLTOSPY benchmark

Follow VLTO with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Transcript intelligence

What changed

Compared with the prior quarter, Veralto moved from maintaining full-year guidance to raising its EPS outlook, reflecting stronger-than-expected Q1 execution. The company expanded its acquisition strategy beyond In-Situ (announced in Q4 2025) to include GlobalVision in PQI, bringing total recent acquisition investment to approximately $1 billion. A new cost-optimization program was introduced, with savings not expected to impact 2026 earnings but delivering roughly 50% of run-rate savings in 2027 and full effect by 2028. The effective tax rate declined from approximately 24.5% post-spin to the low-20% range due to tax planning initiatives. Management also flagged new headwinds not emphasized in Q4, including Iran conflict-related commodity cost pressures and Section 232 tariff impacts.

Guidance delta

Veralto raised its full-year 2026 adjusted EPS guidance to a range of $4.20–$4.28, up from the prior outlook. The prior quarter's guidance had assumed low-to-mid single-digit core sales growth, modest margin expansion, and mid-high single-digit EPS growth. The raised EPS outlook reflects Q1 outperformance, with sales growing approximately 7% and adjusted EPS growing 13%. The cost-optimization program's savings are not expected to materially impact 2026 earnings, with the benefit profile back-end loaded into 2027 and 2028. Capex outlook remains stable.

Key takeaways

  • Q1 sales grew approximately 7% with adjusted EPS up 13%, beating consensus on both metrics — EPS of $1.07 vs. $1.00 estimated, revenue of $1.42B vs. $1.40B estimated.
  • Full-year 2026 EPS guidance was raised to $4.20–$4.28, signaling management confidence in sustained demand.
  • Two acquisitions totaling roughly $1 billion (In-Situ in Water Quality, GlobalVision in PQI) broaden the portfolio and add cross-sell opportunities.
  • A new cost-optimization program targets a step-change in margins, with approximately 50% of run-rate savings in 2027 and full effect by 2028 — no material 2026 earnings impact.
  • Water Quality growth was driven by wastewater reuse and data-center demand, partially offset by continued softness in China municipal water funding.
  • The effective tax rate declined to the low-20% range from approximately 24.5% post-spin, providing an additional tailwind.

Management priorities

  • Execute disciplined M&A integration of In-Situ and GlobalVision across Water Quality and PQI segments.
  • Deliver cost-optimization program savings on schedule, targeting 50% run-rate in 2027 and full effect by 2028.
  • Continue share repurchases to return capital to shareholders.
  • Expand services for data-center water treatment and digital packaging solutions.
  • Maintain pricing discipline amid raw-material inflation and competitor price actions.

Related earnings events

Industrials

Sources

  1. Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
  2. FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
  3. Polygon adjusted daily market bars · 2026-07-30T22:31:49.622662+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-07-30T22:31:49.619615+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.